Читать книгу The SAGE Encyclopedia of Stem Cell Research - Группа авторов - Страница 244

Inhibitors of poly (adenosine diphosphate-ribose) polymerase (PARP) are another class of agents that may be particularly useful in BRCA-mutated breast cancer, of which the majority are triple negative. The role of PARP inhibitors in the treatment of triple-negative breast cancer continues to be an active area of investigation. However, they are not commercially available for use.

PARP is involved in the molecular events leading to cell recovery from DNA damage. When PARP1, the most abundant member of the PARP family, is inhibited, double-strand DNA breaks accumulate and under normal conditions are repaired via the BRCA pathway-dependent homologous recombination mechanism. Investigators hypothesized that inhibition of PARP, in combination with DNA-damaging chemotherapeutics, would render tumors lacking BRCA function extremely sensitive. Given the shared clinicopathologic characteristics between BRCA-mutated and triple-negative breast cancers, the efficacy and safety of PARP inhibition is being tested in both settings. There are several PARP inhibitors in clinical development, such as olaparib, veliparib, and iniparib.